Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jan 19;10(1):186.
doi: 10.3390/cells10010186.

ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients

Affiliations
Observational Study

ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients

Alice G Vassiliou et al. Cells. .

Abstract

Endotheliopathy is suggested to be an important feature of COVID-19 in hospitalized patients. To determine whether endotheliopathy is involved in COVID-19-associated mortality, markers of endothelial damage were assessed in critically ill COVID-19 patients upon intensive care unit (ICU) admission. Thirty-eight critically ill COVID-19 patients were included in this observational study, 10 of whom died in the ICU. Endothelial biomarkers, including soluble (s)E-selectin, sP-selectin, angiopoietin 1 and 2 (Ang-1 and Ang-2, respectively), soluble intercellular adhesion molecule 1 (sICAM-1), vascular endothelial growth factor (VEGF), soluble vascular endothelial (VE)-cadherin, and von Willebrand factor (vWf), were measured upon ICU admission. The ICU cohort was subsequently divided into survivors and non-survivors; Kaplan-Meier analysis was used to explore associations between biomarkers and survival, while receiver operating characteristic (ROC) curves were generated to determine their potential prognostic value. sE-selectin, sP-selectin, Ang-2, and sICAM-1 were significantly elevated in ICU non-survivors compared to survivors, and also associated with a higher mortality probability in the Kaplan-Meier analysis. The prognostic values of sE-selectin, Ang-2, and sICAM-1 from the generated ROC curves were greater than 0.85. Hence, we conclude that in our cohort, ICU non-survivors had higher levels of specific endothelial markers compared to survivors. Elevated levels of these markers upon ICU admission could possibly predict mortality in COVID-19.

Keywords: COVID-19; angiopoietin; endotheliopathy; mortality; sE-selectin; sICAM-1; sP-selectin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Intensive care unit (ICU) admission levels of sE-selectin, sP-selectin, Ang-2, sICAM-1, and vWf in survivors and non-survivors. (a) sE-selectin, (b) sP-selectin, (c) Ang-2, (d) sICAM-1, and (e) vWf levels were measured in 38 critically ill patients upon ICU admission (within 24 h). Patients were subsequently categorized as survivors (N = 28) and non-survivors (N = 10). Two-group comparisons were performed with the non-parametric Mann–Whitney test, * p < 0.05, ** p < 0.01, *** p < 0.001. Data are presented as scatter plots, indicating the median value and 25th to 75th centiles. Dashed line, median value of whole cohort (N = 38). Ang-2 = Angiopoietin-2; s = soluble; sICAM-1 = soluble Intercellular adhesion molecule 1; vWf = von Willebrand factor.
Figure 2
Figure 2
Spearman’s correlation coefficient analysis was performed on sE-selectin, sP-selectin, Ang-2, sICAM-1, and vWf levels measured upon intensive care unit (ICU) admission (within 24 h). (a) sE-selectin and Ang-2 (rs = 0.389, p = 0.031), (b) sE-selectin and sICAM-1 (rs = 0.686, p < 0.0001), (c) sE-selectin and sP-selectin (rs = 0.398, p = 0.013), (d) Ang-2 and sICAM-1 (rs = 0.545, p = 0.002), (e) sP-selectin and sICAM-1 (rs = 0.362, p = 0.026), and (f) sP-selectin and vWf (rs = 0.513, p = 0.001). Ang-2 = Angiopoietin-2; s = soluble; sICAM-1 = soluble intercellular adhesion molecule 1; vWf = von Willebrand factor.
Figure 3
Figure 3
Biomarker levels on admission and intensive care unit (ICU) survival probability. (a) sE-selectin, (b) sP-selectin, (c) Ang-2, (d) sICAM-1. sE-selectin, sP-selectin, Ang-2, and sICAM-1 were measured upon ICU admission (within 24-h). The Kaplan–Meier method was used for ICU survival probability estimation and the log-rank test for two-group comparison. The ICU patient cohort was dichotomized above and below the respective median value of each biomarker. Solid lines: ≥median value (high group); dashed lines: <median value (low group). The respective median time to mortality for the two aforementioned groups were as follows: (a) sE-selectin, 44 days (95% CI: 28–61) for the high group, and 56 days (95% CI: 53–58) for the low group (Log-Rank test, p = 0.038); (b) sP-selectin, 35 days (95% CI: 26–43) for the high group, and 85 days (95% CI: 71–98) for the low group (Log-Rank test, p = 0.009); (c) Ang-2, 43 days (95% CI: 26–61) for the high group, and 79 days (95% CI: 57–101) for the low group (Log-Rank test, p = 0.048); (d) sICAM-1, 42 days (95% CI: 27–57) for the high group, and 85 days (95% CI: 73–98) for the low group (Log-Rank test, p = 0.022). Ang-2 = Angiopoietin-2; s = soluble; sICAM-1 = soluble Intercellular adhesion molecule 1.
Figure 4
Figure 4
Admission biomarker levels and intensive care unit (ICU) mortality. Receiver operating characteristic (ROC) curve analysis. ROC curves were generated to determine the prognostic accuracy of either sE-selectin, Ang-2 or sICAM-1, as measured on ICU admission (within 24-h). (a) ROC curves; sE-selectin, solid line; Ang-2, dashed line; sICAM-1, dotted line. (b) The corresponding areas under the curve (AUC), 95% confidence intervals (CI) and the optimal cut-off values with the greatest combined sensitivity and specificity are given. * p-value < 0.05. Ang-2 = Angiopoietin-2; s = soluble; sICAM-1 = soluble Intercellular adhesion molecule 1.

Similar articles

Cited by

References

    1. Gustafson D., Raju S., Wu R., Ching C., Veitch S., Rathnakumar K., Boudreau E., Howe K.L., Fish J.E. Overcoming Barriers: The Endothelium as a Linchpin of Coronavirus Disease 2019 Pathogenesis? Arter. Thromb. Vasc. Biol. 2020;40:1818–1829. doi: 10.1161/ATVBAHA.120.314558. - DOI - PMC - PubMed
    1. Chau A.S., Weber A.G., Maria N.I., Narain S., Liu A., Hajizadeh N., Malhotra P., Bloom O., Marder G., Kaplan B. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. Arthritis Rheumatol. 2021;73:23–35. doi: 10.1002/art.41526. - DOI - PubMed
    1. Marchetti M. COVID-19-driven endothelial damage: Complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure. Ann. Hematol. 2020;99:1701–1707. doi: 10.1007/s00277-020-04138-8. - DOI - PMC - PubMed
    1. Jung F., Krüger-Genge A., Franke R.P., Hufert F., Küpper J.H. COVID-19 and the endothelium. Clin. Hemorheol. Microcirc. 2020;75:1–5. doi: 10.3233/CH-209100. - DOI - PMC - PubMed
    1. Goshua G., Pine A.B., Meizlish M.L., Chang C.H., Zhang H., Bahel P., Baluha A., Bar N., Bona R.D., Burns A.J., et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7:e575–e582. doi: 10.1016/S2352-3026(20)30216-7. - DOI - PMC - PubMed

Publication types